The embryonic stem cell test (EST) is a validated in vitro alternative test for prediction of embryotoxicity with inhibition of cardiomyocyte differentiation under the microscope as beating areas at day 10 as an endpoint. However, improvements are necessary for regulatory acceptance and application to highthroughput screening. We have previously reported that heart and neural crest derivatives expressed transcript 1 (Hand1), a transcription factor essential for mammalian heart development, and cardiomyopathy associated 1 (Cmya1), an intercalated disk protein implicated in cardiac morphogenesis, are quantitative and objective molecular endpoints for predicting embryotoxicity, detected at day 6 when mouse embryonic stem (ES) cells differentiate into cardiomyocytes. In established stable transgenic ES cells with Hand1 or Cmya1 promoters upstream of luciferase reporter gene, changes in each gene expression were found to be coincident with those in luciferase activities during cardiomyocyte differentiation, suggesting that monitoring might be possible by chemiluminescent determination. In our novel EST, differentiation toxicity and cytotoxicity of test chemicals were here analyzed using ES cells and 3T3 fibroblasts by this approach in 96-microwell plates. Extensive investigations were performed to explore predictive power and validity by comparing a set of 24 well-known test chemicals. The novel EST offers high predictability and accuracy with a reduced test duration and manpower compared with the original EST protocol, thus providing a new rapid and sensitive in vitro method for screening embryotoxicants.
It has been reported that the highest numbers of experimental animals are currently used in regulatory reproductive and developmental toxicology (Hartung, 2009; Spielmann and Vogel, 2006) . Therefore, development of effective in vitro alternative test methods for prediction of toxicity is a high priority. The European Center for Validation of Alternative Methods (ECVAM) has assessed the embryonic stem cell test (EST), the rat whole-embryo culture test, and the micromass test as alternative testing methods . Of these three, the EST, which uses two permanent cell lines, the pluripotent embryonic stem (ES) cell line D3 and differentiated 3T3 fibroblasts, is the only approach in which no pregnant animals have to be sacrificed (Spielmann et al., 1997) . The EST predicts developmental toxicity based on inhibition of the differentiation of ES cells into cardiomyocytes. With more than 20 reference compounds having differing embryotoxic potency (strong, weak, and nonembryotoxic), the EST provided a correct judgment in 78% of experiments, a predictivity of 100% being obtained for strong embryotoxicants . Recently, embryotoxicity of the variety of compounds such as pharmaceuticals (Eckardt and Stahlmann, 2010; Paquette et al., 2008) , cosmetics (Chen et al., 2010) , industrial chemicals (de Jong et al., 2009) , nanoparticles (di Guglielmo et al., 2010) , and heavy metals (Stummann and Bremer, 2008) were assessed by the EST. Although it is considered a promising alternative assay for reproductive and developmental toxicity, optimization to allow successful regulatory implementation including improvement of the prediction models, expansion of the database, adoption of a metabolic system, and additional major target tissue cells have been proposed . Because accepted in vitro methods for regulatory purposes are not yet available, opportunities for refinement of standard in vivo tests have also been discussed, with a particular focus on reduction of the number of animals used in developmental and reproductive toxicity testing (Spielmann, 2009 ). For screening purposes, an in vitro approach would still be necessary. However, the current experimental procedure of the EST with an outcome based on visual assessment of the contracting cardiomyocytes is time consuming and requires extensive experimental expertise. In addition, the test duration of 10 days is rather long. Previously, we identified genes demonstrating up-and downregulation during ES cell differentiation into cardiomyocytes and neurons by DNA microarray analysis, several being specifically altered by embryotoxic chemicals (Suzuki et al., 2011) . In the present study, we focused on heart and neural crest derivatives expressed transcript 1 (Hand1) and cardiomyopathy associated 1 (Cmya1) as new molecular endpoints of the EST for early detecting differentiation toxicity of chemicals on day 6. Hand1, a basic helix-loop-helix transcription factor known to be indispensable in heart development, is reported to display dynamic and spatially restricted expression patterns in the developing heart (Cross et al., 1995) . The intercalated disk protein Cmya1 (Xin) was originally discovered in chicken striated muscle and implicated in cardiac morphogenesis (Wang et al., 1999) . The hearts of Xina-null mice are hypertrophied and exhibit fibrosis, indicative of cardiomyopathy (Gustafson-Wagner et al., 2007) . Moreover, expression of Hand1 and Cmya1 is observed from day 6 of ES cell differentiation into cardiomyocytes. In the present study, at first, we established stable transgenic ES cells with Hand1 or Cmya1 promoters upstream of luciferase reporter gene (Hand1-or Cmya1-ES). Next, using 96-well multiplate-based new protocols with Hand-and Cmya1-ES cells (Hand1-and Cmya1-ESTs, respectively), inhibitory effects of 24 test chemicals with well-characterized embryotoxic potential in vivo on the differentiation and proliferation of the transgenic ES and differentiated 3T3 cells was analyzed at day 6 by chemiluminescent determination. The aim was to evaluate predictive capacity and validity of our newly developed Hand1-and Cmya1-ESTs. The present study is the first step to development of novel in vitro methods for screening embryotoxicants and prediction of in vivo developmental toxicity.
MATERIALS AND METHODS
Chemicals. Twenty-four chemicals (Table 1 ) used in the ECVAM international validation study (Brown, 2002; Genschow et al., 2004) were purchased from Sigma-Aldrich (St Louis, MO) and dissolved in appropriate solvents, that is, PBS, dimethyl sulfoxide, or ethanol as indicated (Table 1) . The purity of all chemicals tested was more than 98.0%.
Construction of plasmids. The Hand1-promoter-luc plasmid was generated by insertion of a 5-kb fragment upstream of the transcription start site of the Hand1 gene (NCBI accession number: NM_008213.2) into the KpnI site of the pGL4.17 [luc2/Neo] luciferase vector (Promega, Japan). The 5-kb DNA fragment amplified from genomic DNA of ES-D3 cells using primers (5#-CCCACCATCCATTTCGCTCC-3# and 5#-CGGATTCCCATCATCG CTCC-3#) by PrimeSTAR HS DNA Polymerase (TAKARA BIO, Inc., Kyoto, Japan), and the pGL4.17 vector were digested with KpnI and ligated using a DNA Ligation Kit (TAKARA BIO, Inc.). The Cmya1-promoter-luc plasmid was generated by insertion of a 8-kb fragment upstream of the transcription start site of the Cmya1 gene (NCBI accession number: NM_011724.3) into the KpnI site of the pGL4.17 [luc2/Neo] luciferase vector. The 8-kb DNA fragment amplified from genome DNA of mouse bacterial artificial chromosome clone (clone ID: bMQ-323I6; DANAFORM, Kanagawa, Japan) using primers (5#-CCTTCTGGGAAGAAGGGGAG AACCTG-3# and 5#-ACAGAGAGACCC TATCTCTAAAG-3#) by PrimeSTAR HS DNA polymerase and the pGL4.17 vector were digested with KpnI and ligated. The plasmid sequences were verified by automated sequencing (Applied Biosystems, Foster City, CA).
Development of stable transgenic ES cells. Mouse ES cells of line D3
purchased from the American Type Culture Collection (ATCC) were cultured with maintenance culture media containing high glucose (4.5 g glucose/l), Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) containing 15% fetal calf serum (Hyclone, South Logan, UT), 2mM glutamine (Invitrogen), antibiotics (50 U/ml penicillin and 50 lg/ml streptomycin; Nacalai tesque, Kyoto, Japan), 1% nonessential amino acids (Invitrogen), 0.1mM 2-mercaptoethanol (Sigma-Aldrich), and 1000 U/ml murine leukemia inhibitory factor (mLIF; Millipore, Japan) as described previously (Spielmann et al., 1997) . Cells maintained in 60-mm 2 cell culture dishes (BD Falcon, Japan) under 5% CO 2 and 95% humidity at 37°C were passaged every 2-3 days. Linearized Hand1 or Cmya1-promoter-Luc plasmids (2 lg) were transfected into mouse ES cells by a lipofection method (Lipofectamine, 2000; Invitrogen) according to the manufacturer's protocols. The transfected cells were dissociated into single cells with trypsin/EDTA (nacalai tesque, Japan) and transferred to 96-well tissue culture plates in maintenance culture medium containing 100 lg/ml of G418 (Wako Pure Chemicals, Japan) (selection medium). To isolate stable transgenic ES cells, the cells were cultured for 1 week, G418-resistant colonies being picked up, dissociated with trypsin/EDTA, and cultured in the selection medium. This selection process was repeated four to five times.
Characterization of stable transgenic ES cells. To confirm the integration of exogenous DNA into the genome of the selected stable transgenic ES cells (Hand1-or Cmya1-ES), amplification of the Hand1 or Cmya1 promoter regions with the luciferase reporter gene was analyzed by PCR. Furthermore, the cells were differentiated into cardiomyocytes as described previously (Seiler et al., 2006; Spielmann et al., 1997) with minor modification. Briefly, 750 cells in 100 ll differentiation medium (the maintenance culture medium without mLIF to allow differentiation) were seeded in custom-made white round-bottom lowattachment 96-well plates (MS-9096W; Sumitomo Bakelite, Co. Ltd, Japan) and incubated for 4-10 days at 37°C under 5% CO 2 and 95% humidity. To confirm driving of the exogenous reporter construct in the cells, luciferase activity was measured periodically in differentiated cells lysed by adding 100 ll per well of Steady-Glo Luciferase Assay System (Promega) and then placed at room temperature for 30 min with light shaking. Luminous intensity was measured in a microplate luminescence counter (TopCount NXT; Packard BioScience Co., Meriden, CT). Expression levels of mRNAs of the endogenous Hand1 and Cmya1 genes in the differentiated cells were analyzed by quantitative real-time PCR methods. Reverse transcription was performed with SuperScript III for 50 min at 42°C, and oligo (dT) as a primer, using 300 ng of total RNA. The mRNA was quantified with TaqMan gene expression assays (Applied Biosystems, Japan) in a 7900H Fast Real-Time PCR System, with a two-step PCR procedure according to a manufacturer's protocol. The thermal cycling conditions were: 95°C for 20 s for the first cycle, followed by 40 cycles of 95°C for 3 s and 60°C for 20 s. The TaqMan probes used in the present study were Mm00433931_m1 (Hand1) and Mm00495998_m1 (Cmya1). Hand1 and Cmya1 mRNA expression levels were normalized against b-actin as an internal control.
Differentiation and cytotoxicity assays. Differentiation toxicity was analyzed by detecting chemical-related changes in Hand1 and Cmya1 promoter-derived luminescence during differentiation of Hand1-and Cmya1-ES cells, respectively, into cardiomyocytes. Cells in 50 ll of differentiation medium (750 cells per well) were seeded in white round-bottom lowattachment 96-well plates (Sumitomo Bakelite, Co. Ltd). Chemicals dissolved in 50 ll of differentiation medium were added into the plates (12 wells per concentration), followed by incubation for 6 days at 37°C under 5% CO 2 and 95% humidity. The luciferase activities were measured according to the procedure described above. Inhibition of differentiation was expressed as the concentration of the test chemical that reduced the luminescence by 50% (Hand1-or Cmya1-ES-ID 50 , calculated from the concentration-response curve). Cytotoxicity of individual transgenic ES cells was determined using the following previously described method (Scholz et al., 1999) with minor changes. Cells were seeded into a 96-well tissue culture plate (500 cells per well) in differentiation medium with or without the test chemicals. Cytotoxicity of BALB/c 3T3 fibroblasts (ATCC) was assessed as detailed earlier (Scholz DEVELOPMENT OF A NOVEL HIGH-THROUGHPUT EST 461 et al., 1999). The viability of the transgenic ES cells and BALB/c 3T3 cells was measured at day 6 using the CellTiter Glo Non-Radioactive Cell Proliferation Assay (Promega) based on the MTT assay, according to the manufacturer's instructions. Cytotoxicity was expressed as the concentration of the compound reducing the viability of cells to 50% of the control level (Hand1-or Cmya1-ES-IC 50 and 3T3-IC 50 , determined from concentration-response curves).
Statistical analysis of the dose-response curves from differentiation toxicity and cytotoxicity assays was carried out using GraphPad Prism version 4.00 (GraphPad Software, San Diego, CA). Correlations between three endpoint values obtained with both novel ESTs were assessed based on pairwise scatter plots, and the determination coefficients (R 2 ) were determined for each endpoint. In the novel ESTs with Hand1-and Cmya1-ES cells (Hand1-and Cmya1-ESTs, respectively), the embryotoxic potency of test compounds in vivo was predicted using a biostatistically based prediction model (PM) .
RESULTS

Establishment of Stable Transgenic ES Cells for Detecting
Hand1 and Cmya1 Gene Expression Stable transgenic ES cells with Hand1-or Cmya1 promoterluciferase fragments were established and characterized. As shown in Figure 1A , exogenous DNA fragments derived from Hand1-and Cmya1 promoter-luciferase sequences were clearly detected in genomic DNA only from the transgenic cells. Differentiation studies of the Hand1-ES cells into cardiomyocytes showed that endogenous Hand1 expression increased from day 5, reached a maximum at 6 days, and decreased thereafter (Fig. 1B) . Changes in the gene expression were coincident with those in luciferase activities during the cardiomyocyte differentiation (Fig. 1C) . Endogenous Cmya1 gene expression increased from day 5, reached a peak level at day 7, and thereafter was maintained at a high level (Fig. 1B) . Changes in endogenous Cmya1 gene expression were also coincident with those in luciferase activity during the cardiomyocyte differentiation (Fig. 1C) . These results indicate that chemiluminescent determination can easily and conveniently measure Hand1 and Cmya1 gene expression in Hand-and Cmya1-ES cells, respectively.
Analysis of Differentiation Toxicity and Cytotoxicity of Strong Embryotoxic Compounds with Hand-and Cmya1-ES Cells
Differentiation toxicity and cytotoxicity of 24 compounds (Table 1) were analyzed using Hand1-ES, Cmya1-ES, and BALB/c 3T3 cells. Three endpoints for Hand1-EST (Hand1-ES-ID 50 , Hand1-ES-IC 50 , and 3T3-IC 50 ) or Cmya1-EST (Cmya1-ES-ID 50 , Cmya1-ES-IC 50 , and 3T3-IC 50 ) were examined as illustrated in Figure 2 . Hand1-and Cmya1-ES-ID 50 values were taken as indicators of differentiation toxicity in the new ESTs. All studies were in 96-well plates based on 6-day experiments and chemiluminescent detection. The three endpoints with seven strong embryotoxic compounds were determined in the Hand1-and Cmya1-ESTs (Tables 2 and 3, Figure 3A . In the case of MTX exposure, Hand1-and Cmya1-ES-IC 50 values were the same as respective Hand1-and Cmya1-ES-ID 50 values. In contrast, the Hand1-and Cmya1-ES-ID 50 values for 6-AN (0.50 and 0.87 lg/ml, respectively) were low as compared with individual Hand1-or Cmya1-ES-IC 50 values (1.39 and 1.48 lg/ml, respectively), suggesting that the observed inhibition of luciferase activity during ES cell differentiation into cardiomyocytes was not entirely due to cytotoxicity. Interestingly, the Cmya1-ES-ID 50 (0.17 lg/ml) showed a dramatically high value as compared with Cmya1-ES-IC 50 (0.00298 lg/ml) with RA exposure, the phenomenon being reproducible (data not shown). Differentiation toxicity and cytotoxicity in Hand1-or Cmya1-EST with MTX and 6-AN exposures are demonstrated in Figures 3B and C, respectively.
Analysis of Differentiation Toxicity and Cytotoxicity of Weak Embryotoxic Compounds with Hand-and Cmya1-ES Cells
The three endpoints for nine weak embryotoxic compounds were determined in the Hand1-and Cmya1-ESTs (Tables 2  and 3 Total RNAs (mixture of 12 wells/day) were extracted during Hand1-and Cmya1-ES cell differentiation into cardiomyocytes periodically and then subjected to real-time PCR analysis of Hand1 and Cmya1 expression. Each data point represents the mean ± SD of three independent experiments. (C) Hand1-ES and Cmya1-ES cells were differentiated into cardiomyocytes, and luciferase activity was periodically analyzed. Each data point represents the mean ± SD (n ¼ 12 wells).
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individual ES-IC 50 values with all the compounds using both Hand1-and Cmya1-ESTs, suggesting specific potential for differentiation toxicity of the test compounds. Interestingly, VPA, DPH, and CAF exposure caused stronger inhibitory effects (more than 10-fold) on differentiation (Hand1-ES-ID 50 values) as compared with cytotoxicity (Hand1-ES-IC 50 values) in the Hand1-EST. However, in the Cmya1-EST, stronger inhibitory effects (more than 10-fold) on differentiation (Cmya1-ES-ID 50 values) as compared with cytotoxicity (Cmya1-ES-IC 50 values) were only shown in the DEX and BA cases. These results suggest that there are specific effects of individual test compounds with the two molecular markers. Dose-dependent increases in differentiation toxicity and cytotoxicity with selected weak embryotoxic compounds, (A) CAF, (B) DEX, and (C) MAA, in Hand1-and Cmya1-ESTs are presented in Figure 4 .
Analysis of Differentiation Toxicity and Cytotoxicity of Nonembryotoxic Compounds with Hand-and Cmya1-ES Cells
The three endpoints for eight nonembryotoxic compounds were analyzed in the Hand1-and Cmya1-ESTs (Tables 2 and 3,  respectively) . No clear decreases in luciferase activity was observed with PenG, SAC, CAM, and DMP (Cmya1-ES only) exposure, no Hand1-and Cmya1-ES-ID 50 values being determined with the concentration of 1000 lg/ml (Tables 2  and 3 ). Hand1-or Cmya1-ES-IC 50 values were similar to respective 3T3-IC 50 values with all nonembryotoxic compounds, showing no apparent differences in susceptibility between ES and 3T3 cells. ES-ID 50 values were the same or higher than ES-IC 50 and 3T3-IC 50 values with PenG, SAC, AsA, CAM, and INH in both Hand1-and Cmya1-ESTs, indicating no specific differentiation toxicity. Surprisingly, the Hand1-ES-ID 50 value (9.09 lg/ml) was dramatically lower than Cmya1-ES-ID 50 value (> 1000 lg/ml) with DMP (< 100th). Data from analysis of cytotoxicity and differentiation toxicity with selected nonembryotoxic compounds (PenG, INH, and DMP) in Hand1-and Cmya1-ESTs are presented in Figure 5 .
Comparison of Three Endpoint Values between Hand1-EST and Cmya1-EST
As expected, 3T3-IC 50 values in Hand1-EST and Cmya1-EST were almost the same for individual compounds (R 2 ¼ 0.9979) (Fig. 6A) , indicating high reproducibility of the cytotoxicity tests. As was the case for 3T3-IC 50 values, Hand1-ES-IC 50 values for individual compounds were almost the same as those of Cmya1-ES-IC 50 (R 2 ¼ 0.9951) (Fig. 6B ), indicating no differences in toxic responses to various test compounds between the genetically engineered Hand1-and Cmya1-ES cells. However, some variation in ES-ID 50 values for individual compounds was detected between Hand1-and Cmya1-EST (R 2 ¼ 0.6851) (Fig. 6C) . Hand1-and Cmya1-ES-ID 50 values were below 2.90 and 3.82 lg/ml (HU cases), respectively, with strong embryotoxic compounds. With weak embryotoxic compounds, Hand1-and Cmya1-ES-ID 50 values were 5.31-446.77 and 3.19-379.23 lg/ml, respectively, the same or greater than with strong embryotoxic compounds. Hand1-and Cmya1-ES-ID 50 values of the nonembryotoxic compounds were 9.09 to > 1000 and 5.23 to > 1000 lg/ml, respectively, being greater than those of strong and weak embryotoxic compounds. These results show that differentiation toxicity (ES-ID 50 values) correlates well with the magnitude of teratogenicity in vivo with the test compounds used in the present study.
Classification of Test Chemicals in the Hand1-and Cmya1-ESTs
The test chemicals were classified by the ECVAM PM reported previously using three endpoints in Hand1-and Cmya1-ESTs (Table 4) . Of the seven strong embryotoxic compounds, all except for HU were classified as ''Strong'' with both ESTs. All nine weak embryotoxic compounds were predicted to be ''Weak.'' In the Hand1-EST, five of eight nonembryotoxic compounds were classified as ''Non,'' seven of eight nonembryotoxic compounds being classified as ''Non'' in the Cmya1-EST. DHM was misclassified as ''Weak'' with both of the present ESTs, in line with the validated EST reported previously . The precision, productivity, and overall accuracy of Hand1-and Cmya1-EST are compared with those of the validated EST, recalculated on the basis of 24 chemicals used in the present study, in Table 5 . Predictivity for strong, weak, and nonembryotoxic categories was calculated (the percentage of compounds correctly identified by the EST within each true in vivo risk category) in the Hand1-EST (86, 100, and 63%, respectively), Cmya1-EST (86, 100, and 88%, respectively), and the validated EST (100, 71, and 78%, respectively). The precision for strong, weak, and nonembryotoxic categories was calculated for the Hand1-EST (100, 69, and 100%, respectively), Cmya1-EST (100, 82, and 100%, respectively), and the validated EST (91, 82, and 71%, respectively). Overall DEVELOPMENT OF A NOVEL HIGH-THROUGHPUT EST 465 accuracy of the Hand1-, Cmya1-, and validated ESTs was calculated to be 83, 92, and 81%, respectively. These results show that predictivity and precision are about the same among the Hand1-, Cmya1-, and validated ESTs. Moreover, overall accuracy of the present ESTs is identical to or higher than that of the validated EST. 
DISCUSSION
In the present study, we focused on expression of Hand1 and Cmya1 during mouse ES cell differentiation into cardiomyocytes, using luciferase expression as a surrogate. The results showed reliable results at 6 days, much shorter than the 10 days required for microscopic examination of contracting cardiomyocytes in the original EST.
In recent decades, a number of studies have reported a shortening of the duration of the EST, as well as an enhancing of the throughput capacity by incorporating well-known molecular cardiomyocyte markers such as a-actin (Bremer et al., 2001) , myosin heavy chain (Bremer et al., 2001; Pellizzer et al., 2004; Seiler et al., 2004; zur Nieden et al., 2001 zur Nieden et al., , 2004 , Nkx2.5 (Pellizzer et al., 2004) , and a-actinin . We have previously reported on marker genes involved in the embryotoxicity from the gene group under cardiomyocyte and neuron differentiation processes (Suzuki et al., 2011) .
The luciferase reporter gene assay is known to be a widespread method for quantification of target gene expression easily and sensitively, being used for mechanistic studies involved in transcription (Ooe et al., 2009) and various assays in pharmacological and toxicological areas. Previously, we have analyzed the effects of chemicals on estrogen receptors in humans (Saito et al., (Sumida and Saito, 2008; Sumida et al., 2003) by the luciferase reporter assays for assessing endocrine-disrupting effects of chemicals. We have also established the transgenic cells stably transfected human estrogen receptor-a and the luciferase reporter gene (HeLa-9903), the reporter gene assay using HeLa-9903 being adopted as an OECD guideline for detection of estrogenic agonist activity of chemicals (OECD, 2009) . Therefore for the present study, stable transgenic ES cells with Hand1-or Cmya1 promoter-luciferase fragment were established and characterized. As shown in Figures 1B and C , gene expression of endogenous Hand1 and Cmya1 were also coincident with those in luciferase activities during the cardiomyocyte differentiation, confirming the feasibility of monitoring by chemiluminescent determination. As illustrated in Figure 2 , three endpoints for Hand1-EST (Hand1-ES-ID 50 , Hand1-ES-IC 50 , and 3T3-IC 50 ) or Cmya1-EST (Cmya1-ES-ID 50 , Cmya1-ES-IC 50 , and 3T3-IC 50 ) were obtained from 96-well plates-based 6-day experiments and chemiluminescent detection. For the analysis of differentiation toxicity with the high-throughput screening (HTS) using 96-well plates in the original EST, replacement of the labor-intensive 'hanging drop' culture by a low cell-binding well plate was reported (Peters et al., 2008) . However, special plates applicable for luminescence measurement are indispensable for luciferase assays. Therefore, we made original white low-attached round-bottom 96-well plates for luciferase assays to analyze differentiation toxicity (represented as Hand1-and Cmya1-ES-ID 50 values) in the present study, the plates offering a dramatic advance for the assays from the standpoints of sensitivity, accuracy, and convenience. Prior to the present study, within-laboratory variability of each endpoint value in Hand1-or Cmya1-EST has been studied using the plates and some test compounds, reproducibility of the three endpoint (Festag et al., 2007; Pellizzer et al., 2004; zur Nieden et al., 2004) , green fluorescence protein-reporter assay by fluorescence-activated cell sorting (FACS) (Bremer et al., 2001) , and antibody-based FACS analysis (Buesen et al., 2009; Seiler et al., 2004) . Quantitative real-time PCR analysis is a generally used quantitative method for mRNA expression, but it is not adequate for applying the HTS. The antibody-based FACS is a promising analytical method as a sensitive, more rapid, and reproducible detection of molecular markers. However, microplate luminescence counters for luciferase assays with new ESTs are inexpensive and time saving as compared with equipment for FACS analysis with HTS apparatus. Moreover, there are no preparation steps for analytical samples with the new ESTs. Actually, all data from the 24 compounds could be obtained in the same experiment all at once in the present study, showing that the new ESTs using Hand1 and Cmya1-ES cells are more convenient and time saving than the ESTs as previously reported.
Recently, a new concept-based luciferase reporter assay (ReProGlo) to study adverse effects of chemicals by analyzing effects of test chemicals on a developmentally important signaling pathway, the canonical Wnt/b-catenin/TCF pathway, was reported (Uibel et al., 2010) . However, the assay detects only effects of test chemicals activating or inactivating proteins within the Wnt pathway, which is known to be relevant for early embryonic development. Therefore, additional pathways of importance for embryonic development should be analyzed to improve the predictability of the assay.
Differentiation toxicity and cytotoxicity of strong, weak, and nonembryotoxic compounds could here be analyzed with new ESTs using Hand1 and Cmya1-ES cells (Tables 2 and 3) . 3T3-and ES-IC 50 values in Hand1-EST were correlated well with those in Cmya1-EST (Figs. 6A and B) . Hand1-ES-ID 50 values of strong, weak, and nonembryotoxic compounds were below 2.90, 5.31-446.77, and 9.09 to > 1000 lg/ml, respectively. In the case of Cmya1-ES-ID 50 , values of strong, weak, and nonembryotoxic compounds showed below 3.82, 3.19-379.23, and 5.23 to > 1000 lg/ml, respectively. Therefore, values of Hand1-ES-ID 50 with strong, weak, and nonembryotoxic compounds tested in the present study were similar to those of Cmya1-ES-ID 50 , correlating with teratogenic potency of the compounds in vivo. However, the determination coefficients between Hand1-and Cmya1-ES-ID 50 values for individual compounds were comparatively low (R 2 ¼ 0.6851) (Fig. 6C ) because values of the Hand1-ES-ID 50 from some compounds such as RA, VAP, DPH, CAF, SA, and DMP were apparently different from those of the Cmya1-ES-ID 50 . RA exposure, which caused dramatically high Cmya1-ES-ID 50 values as compared with Hand1-ES-ID 50 and Cmya1-ES-IC 50 values (Tables 2 and 3) , likely due to induction of Cmya1-promoter-dependent luciferase activity (data not shown). RA is a well-known inducer of differentiation of ES cells into a large number of different cell types including neurons, glial cells, adipocytes, chondrocytes, osteocytes, corneal epithelium, skeletal muscle, smooth muscle, and ventricular cardiomyocytes (Soprano et al., 2007) . Therefore, Cmya1 might be induced directly or indirectly under the RA-related pathways. Mechanisms of differences in the ES-ID 50 values of individual compounds have yet to be clarified but Hand1-or Cmya1-specific mechanisms might exist. DMP was classified differently as ''Weak'' and ''Non'' in Hand1-and Cmya1-EST, respectively, by the ECVAM-PM (Table 4 ). In the validation study by ECVAM, DMP was misclassified as ''Weak'' in half of laboratories (Table 4) , so the present study might help clarify the mechanism of the variation of the DMP case. In the seven strong embryotoxic compounds, HU was misclassified as ''Weak'' with both new ESTs, but all the other seven strong embryotoxic compounds were classified as ''Strong,'' suggesting overall efficacy. All nine weak embryotoxic compounds were classified as ''Weak'' in both ESTs, indicating higher predictivity of the weak embryotoxic compounds in the present ESTs (100%) as compared with the validated EST (71%) ( Table 5 ). The higher predictivity was found in the Cmya1-EST regarding nonembryotoxic compounds (88%) (Table 5) ; however, DHM was misclassified as ''Weak'' in both present ESTs, as was the case in the validated EST . The reason is unclear, but the results suggest that predictivity of the present ESTs is identical or superior to that of the validated EST. Moreover, overall accuracy of the Hand1-, Cmya1-, and validated ESTs was calculated to be 83, 92, and 81%, respectively. van Dartel et al. (2009) reported that inhibition of differentiation could be obscured by effects on proliferation of the test compounds because proliferation and differentiation processes both occur in the EST. Therefore, more specific testing of inhibition of cardiomyocyte differentiation could possibly improve the prediction of embryotoxicity in the EST. Furthermore, direct effects of test compounds on inhibition of differentiation can be determined easily by comparing differentiation (ES-ID 50 values) to cytotoxicity (ES-IC 50 values) of ES cells in the present ESTs, implying the reason for higher accuracy rates of our Hand1 and Cmya1-ESTs. Analysis of additional target tissue cells (nerve, bone, and cartilage cells) by teratogens may be important for reduction of false-negative results of the original and our developed ESTs by observation of effects on ES cell differentiation into cardiomyocytes. We also have reported marker genes involved in the embryotoxicity from the gene group under neuron differentiation processes (Suzuki et al., 2011) , 22 genes being molecular endpoints for predicting embryotoxicity during neuron differentiation. Development of the transgenic ES cells for detecting the neuron gene expression will be a strong tool to enhance the predictivity of embryotoxicants.
In summary, new ES cell-based reporter assay systems which detect chemical dependent inhibition of ES cell DEVELOPMENT OF A NOVEL HIGH-THROUGHPUT EST differentiation into cardiomyocytes have been developed using Hand1 and Cmya1 expression as molecular endpoints. The novel ESTs allow convenient determination of differentiation toxicity and cell viability in a short duration high-throughput 96-well microplate format by chemiluminescent detection. Their application has permitted reliable classification of test compounds in accordance with their teratogenic potential in vivo. Our results suggest that the Hand1-and Cmya1-ESTs could have extended utility as in vitro assay systems for screening embryotoxicants. Further studies using a wider selection of test compounds are now necessary to assess the capabilities and limitations of the present ESTs in prediction of embryotoxicity.
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